Eli Lilly and Company (BVL:LLY)

Market Cap	3.05T
Revenue (ttm)	206.01B
Net Income (ttm)	63.84B
Shares Out	n/a
EPS (ttm)	70.87
PE Ratio	47.71
Forward PE	32.00
Dividend	21.50 (2.14%)
Ex-Dividend Date	Nov 14, 2025

Volume	15
Average Volume	2
Open	1,007.00
Previous Close	1,063.50
Day's Range	1,007.00 - 1,007.00
52-Week Range	632.70 - 1,063.50
Beta	n/a
RSI	53.69
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD